What is the mechanism of action of CAMCEVI 42mg?

CAMCEVI is a GnRH agonist containing leuprolide that suppresses pituitary gonadotropin release, reducing testosterone production.

What are I-Med Biotech’s key markets?

Primary markets include the U.S., Europe, and Singapore, with future expansion planned across Asia.

Who are the competitors to CAMCEVI?

In the U.S., competitors include Endo’s Degarelix, but I-Med differentiates with a 3-month dosing interval.

What is I-Med’s core technology?

Proprietary microsphere-based sustained-release technology enabling stable 6-month drug delivery, reducing patient visits.

What is the market size for FP-001?

The global market for central precocious puberty is estimated at several hundred million USD annually, led by the U.S.

I-Med Biotech's Prostate Cancer Drug CAMCEVI 42mg Receives Market Approval in Singapore

Published Jul 20, 2026 8:12 PM ・ Updated Jul 20, 2026 9:11 PM ・ 3 min read ・ Source: PR Times

I-Med Biotech (6576-TW) announced that its partner, Changchun Jinshai Pharmaceutical, has received market approval from Singapore’s Health Sciences Authority (HSA) for CAMCEVI 42mg, a 6-month sustained-release formulation for prostate cancer treatment. The 3-month formulation is expected to launch in Europe and the U.S. in the second half of the year, driving future revenue growth.

I-Med Biotech (6576-TW) announced today (20th) that its licensing partner, Changchun Jinshai Pharmaceutical, has received confirmation from Singapore’s Health Sciences Authority (HSA) that the new drug application for CAMCEVI 42mg, a 6-month sustained-release formulation of leuprolide for prostate cancer, has completed review and been granted market approval.

In addition to the Singapore approval, I-Med Biotech highlighted key upcoming milestones for CAMCEVI. The 3-month formulation is expected to launch sequentially in Europe and the U.S. in the second half of the year, with a potential market size several times larger than the 6-month version. The company anticipates that the dual offering of both 6-month and 3-month formulations will create product portfolio synergies, further enhancing market share and revenue.

Regarding FP-001 42mg, a drug for central precocious puberty, I-Med Biotech plans to submit a New Drug Application (NDA) to the U.S. FDA in the second half of this year, with self-commercialization in the U.S. market targeted by the end of 2027.

The company reported June revenue of NT$10.95 million, down 90.76% month-on-month and 71.84% year-on-year. Cumulative revenue for the first half of the year reached NT$262 million, up 17.9% year-on-year. June’s revenue included NT$7.88 million in royalty income from CAMCEVI’s 6-month formulation sales in the U.S. and European markets, along with NT$3.07 million in service income.

FACT BOX

Source: PR Times
Category: New Product
Products / services: CAMCEVI 42mg / FP-001 42mg

I-Med Biotech's Prostate Cancer Drug CAMCEVI 42mg Receives Market Approval in Singapore

⚡ Key Points

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY